<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158148">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02006693</url>
  </required_header>
  <id_info>
    <org_study_id>MS-001</org_study_id>
    <nct_id>NCT02006693</nct_id>
  </id_info>
  <brief_title>Evaluation of the XEN Implant in Moderate POAG Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>AqueSys, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AqueSys, Inc.</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the AqueSys XEN Implant for the treatment of
      moderate primary open angle glaucoma patients when medications have failed to control
      intraocular pressure (IOP). Effectiveness will be evaluated by comparing medicated
      preoperative, intraocular pressure to postoperative values.  Additionally, the number of IOP
      lowering medications subjects are on at each study visit will be compared to preoperative
      medication.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The number of IOP lowering medications compared to the number of preoperative IOP lowering medications.</measure>
    <time_frame>24 month visit</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of IOP lowering medications compared to the number of preoperative IOP lowering medications.</measure>
    <time_frame>12 month visit</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparing the intraocular pressure to the preoperative medicated intraocular pressure.</measure>
    <time_frame>24 month visit</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparing the intraocular pressure to the preoperative medicated intraocular pressure.</measure>
    <time_frame>12 month visit</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>XEN Gel Stent</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The XEN Gel Stent will be placed as a standalone procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XEN Gel Stent with cataract surgery</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The XEN Gel Stent with cataract surgery, only will occur if the patient is diagnosed with a cataract..</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XEN Gel Stent</intervention_name>
    <description>The XEN Gel Stent will be placed as a standalone procedure.</description>
    <arm_group_label>XEN Gel Stent</arm_group_label>
    <other_name>XEN Glaucoma Implant</other_name>
    <other_name>XEN Gel Stent</other_name>
    <other_name>ab interno</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XEN Gel Stent with cataract surgery</intervention_name>
    <description>Patient has been diagnosed with a cataract and has elected to have cataract surgery. The XEN Gel Stent will be placed along with cataract surgery.</description>
    <arm_group_label>XEN Gel Stent with cataract surgery</arm_group_label>
    <other_name>Cataract combo</other_name>
    <other_name>XEN Gel Stent</other_name>
    <other_name>XEN Glaucoma Implant</other_name>
    <other_name>ab interno</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of primary open angle glaucoma

          -  Subjects are taking at least one and no more than four IOP lowering medications.

        Exclusion Criteria:

          -  Angle Closure Glaucoma

          -  Subject has neovascular, uveitic or angle recession glaucoma or any glaucoma
             associated with vascular disorders

          -  Clinically significant inflammation or infection in the study eye within 30 days
             prior to the preoperative visit (e.g., blepharitis, conjunctivitis, keratitis,
             uveitis, herpes simplex infection)

          -  Presence of conjunctival scarring or prior conjunctival surgery or other conjunctival
             pathologies (e.g., pterygium) in the target quadrant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vanessa Vera, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>AqueSys, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul S Genge, BS</last_name>
    <phone>9494500250</phone>
    <phone_ext>263</phone_ext>
    <email>pgenge@aquesys.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Eye Clinic Bochum-Langendreer</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorg Bocker, MD</last_name>
      <phone>492342993101</phone>
      <email>joerg.boecker@kk-bochcum.de</email>
    </contact>
    <investigator>
      <last_name>Burkhard Dick, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 14, 2014</lastchanged_date>
  <firstreceived_date>December 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>XEN</keyword>
  <keyword>Primary Open Angle Glaucoma</keyword>
  <keyword>Filtration Device</keyword>
  <keyword>Ab interno</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
